Exelixis, Inc. (EXEL)
USD 33.68
(-2.57%)
USD 33.68
(-2.57%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.58 Billion USD | 17.39% |
| 2022 | 1.35 Billion USD | 23.39% |
| 2021 | 1.09 Billion USD | 30.22% |
| 2020 | 841.2 Million USD | 48.83% |
| 2019 | 565.2 Million USD | 45.44% |
| 2018 | 388.62 Million USD | 43.12% |
| 2017 | 271.53 Million USD | 28.01% |
| 2016 | 212.11 Million USD | 38.04% |
| 2015 | 153.65 Million USD | -35.96% |
| 2014 | 239.93 Million USD | 4.44% |
| 2013 | 229.72 Million USD | 42.94% |
| 2012 | 160.71 Million USD | -15.4% |
| 2011 | 189.96 Million USD | -22.05% |
| 2010 | 243.69 Million USD | -10.95% |
| 2009 | 273.66 Million USD | -8.43% |
| 2008 | 298.85 Million USD | -2.8% |
| 2007 | 307.45 Million USD | 36.39% |
| 2006 | 225.42 Million USD | 32.64% |
| 2005 | 169.95 Million USD | 6.61% |
| 2004 | 159.4 Million USD | 8.53% |
| 2003 | 146.87 Million USD | 11.74% |
| 2002 | 131.43 Million USD | 19.87% |
| 2001 | 109.64 Million USD | 27.17% |
| 2000 | 86.22 Million USD | 146.34% |
| 1999 | 35 Million USD | 99.23% |
| 1998 | 17.56 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 403.46 Million USD | 12.52% |
| 2024 Q1 | 341.67 Million USD | -9.16% |
| 2024 Q2 | 343.16 Million USD | 0.44% |
| 2023 Q3 | 470.72 Million USD | 20.08% |
| 2023 Q4 | 376.11 Million USD | -20.1% |
| 2023 Q1 | 365.64 Million USD | -19.83% |
| 2023 Q2 | 391.99 Million USD | 7.21% |
| 2023 FY | 1.58 Billion USD | 17.39% |
| 2022 Q1 | 259.53 Million USD | -19.29% |
| 2022 Q4 | 456.07 Million USD | 45.33% |
| 2022 Q3 | 313.82 Million USD | -2.61% |
| 2022 FY | 1.35 Billion USD | 23.39% |
| 2022 Q2 | 322.24 Million USD | 24.16% |
| 2021 Q4 | 321.57 Million USD | 21.38% |
| 2021 FY | 1.09 Billion USD | 30.22% |
| 2021 Q1 | 261.63 Million USD | 10.53% |
| 2021 Q2 | 247.28 Million USD | -5.49% |
| 2021 Q3 | 264.92 Million USD | 7.13% |
| 2020 Q2 | 174.72 Million USD | 6.01% |
| 2020 FY | 841.2 Million USD | 48.83% |
| 2020 Q3 | 264.94 Million USD | 51.64% |
| 2020 Q4 | 236.71 Million USD | -10.65% |
| 2020 Q1 | 164.81 Million USD | 8.1% |
| 2019 FY | 565.2 Million USD | 45.44% |
| 2019 Q2 | 140.74 Million USD | 14.03% |
| 2019 Q1 | 123.42 Million USD | 12.57% |
| 2019 Q4 | 152.47 Million USD | 2.63% |
| 2019 Q3 | 148.56 Million USD | 5.55% |
| 2018 Q2 | 94.34 Million USD | 4.36% |
| 2018 FY | 388.62 Million USD | 43.12% |
| 2018 Q1 | 90.4 Million USD | 15.23% |
| 2018 Q3 | 92.86 Million USD | -1.57% |
| 2018 Q4 | 109.64 Million USD | 18.08% |
| 2017 Q2 | 68.94 Million USD | 19.96% |
| 2017 Q3 | 66.67 Million USD | -3.29% |
| 2017 FY | 271.53 Million USD | 28.01% |
| 2017 Q1 | 57.47 Million USD | 56.16% |
| 2017 Q4 | 78.45 Million USD | 17.67% |
| 2016 Q2 | 58.8 Million USD | -7.8% |
| 2016 FY | 212.11 Million USD | 38.04% |
| 2016 Q3 | 52.71 Million USD | -10.35% |
| 2016 Q4 | 36.8 Million USD | -30.19% |
| 2016 Q1 | 63.78 Million USD | 57.04% |
| 2015 FY | 153.65 Million USD | -35.96% |
| 2015 Q4 | 40.61 Million USD | -7.55% |
| 2015 Q3 | 43.93 Million USD | 17.8% |
| 2015 Q2 | 37.29 Million USD | 17.23% |
| 2015 Q1 | 31.81 Million USD | -35.62% |
| 2014 Q2 | 67.44 Million USD | -3.01% |
| 2014 Q3 | 53.53 Million USD | -20.62% |
| 2014 Q1 | 69.53 Million USD | 9.97% |
| 2014 Q4 | 49.41 Million USD | -7.69% |
| 2014 FY | 239.93 Million USD | 4.44% |
| 2013 Q1 | 43.28 Million USD | 2.27% |
| 2013 FY | 229.72 Million USD | 42.94% |
| 2013 Q2 | 62.25 Million USD | 43.85% |
| 2013 Q4 | 63.23 Million USD | 3.74% |
| 2013 Q3 | 60.95 Million USD | -2.1% |
| 2012 Q3 | 38.02 Million USD | -3.42% |
| 2012 Q4 | 42.32 Million USD | 11.3% |
| 2012 Q2 | 39.37 Million USD | -3.98% |
| 2012 Q1 | 41 Million USD | 8.5% |
| 2012 FY | 160.71 Million USD | -15.4% |
| 2011 FY | 189.96 Million USD | -22.05% |
| 2011 Q1 | 54.85 Million USD | 14.37% |
| 2011 Q2 | 51.68 Million USD | -5.78% |
| 2011 Q3 | 45.63 Million USD | -11.7% |
| 2011 Q4 | 37.78 Million USD | -17.2% |
| 2010 Q2 | 63.8 Million USD | -13.29% |
| 2010 Q4 | 47.96 Million USD | -17.78% |
| 2010 FY | 243.69 Million USD | -10.95% |
| 2010 Q1 | 73.58 Million USD | -1.07% |
| 2010 Q3 | 58.34 Million USD | -8.57% |
| 2009 Q1 | 62.07 Million USD | -12.02% |
| 2009 Q4 | 74.38 Million USD | 3.6% |
| 2009 Q3 | 71.79 Million USD | 9.75% |
| 2009 Q2 | 65.41 Million USD | 5.38% |
| 2009 FY | 273.66 Million USD | -8.43% |
| 2008 Q3 | 74.53 Million USD | -5.77% |
| 2008 Q2 | 79.09 Million USD | 5.94% |
| 2008 FY | 298.85 Million USD | -2.8% |
| 2008 Q1 | 74.66 Million USD | -17.17% |
| 2008 Q4 | 70.55 Million USD | -5.34% |
| 2007 Q1 | 61.49 Million USD | -3.2% |
| 2007 Q2 | 67.56 Million USD | 9.87% |
| 2007 Q3 | 88.25 Million USD | 30.64% |
| 2007 FY | 307.45 Million USD | 36.39% |
| 2007 Q4 | 90.14 Million USD | 2.13% |
| 2006 FY | 225.42 Million USD | 32.64% |
| 2006 Q1 | 49.17 Million USD | 12.09% |
| 2006 Q2 | 57.62 Million USD | 17.18% |
| 2006 Q3 | 55.1 Million USD | -4.38% |
| 2006 Q4 | 63.52 Million USD | 15.29% |
| 2005 Q3 | 42.29 Million USD | -3.78% |
| 2005 FY | 169.95 Million USD | 6.61% |
| 2005 Q2 | 43.95 Million USD | 10.34% |
| 2005 Q1 | 39.83 Million USD | -1.55% |
| 2005 Q4 | 43.87 Million USD | 3.74% |
| 2004 Q4 | 40.46 Million USD | 2.96% |
| 2004 FY | 159.4 Million USD | 8.53% |
| 2004 Q1 | 39.96 Million USD | 8.14% |
| 2004 Q3 | 39.3 Million USD | 0.04% |
| 2004 Q2 | 39.28 Million USD | -1.7% |
| 2003 Q1 | 35.63 Million USD | 9.02% |
| 2003 Q2 | 37.32 Million USD | 4.73% |
| 2003 Q3 | 36.95 Million USD | -0.97% |
| 2003 FY | 146.87 Million USD | 11.74% |
| 2003 Q4 | 36.95 Million USD | -0.01% |
| 2002 Q3 | 33.4 Million USD | 1.34% |
| 2002 Q1 | 31.46 Million USD | -0.24% |
| 2002 Q2 | 32.96 Million USD | 4.77% |
| 2002 FY | 131.43 Million USD | 19.87% |
| 2002 Q4 | 32.68 Million USD | -2.15% |
| 2001 Q2 | 26.75 Million USD | 12.1% |
| 2001 Q3 | 29.22 Million USD | 9.22% |
| 2001 Q4 | 31.54 Million USD | 7.93% |
| 2001 FY | 109.64 Million USD | 27.17% |
| 2001 Q1 | 23.86 Million USD | 6.03% |
| 2000 FY | 86.22 Million USD | 146.34% |
| 2000 Q2 | 24.54 Million USD | 42.09% |
| 2000 Q3 | 21.88 Million USD | -10.84% |
| 2000 Q1 | 17.27 Million USD | 0.0% |
| 2000 Q4 | 22.51 Million USD | 2.86% |
| 1999 FY | 35 Million USD | 99.23% |
| 1998 FY | 17.56 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -476.523% |
| Alkermes plc | 996.24 Million USD | -59.276% |
| Agenus Inc. | 78.18 Million USD | -1929.567% |
| Aptorum Group Limited | 10.56 Thousand USD | -15017655.063% |
| Ardelyx, Inc. | 169.93 Million USD | -833.744% |
| Dyadic International, Inc. | 9.15 Million USD | -17236.706% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -7030.616% |
| Lantern Pharma Inc. | 17.87 Million USD | -8775.792% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -23470.844% |
| Novavax, Inc. | 779.12 Million USD | -103.661% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -1857.484% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -1830.478% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -8071.459% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -5259.643% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -2886.795% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -317.028% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -6428.167% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -4090.171% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -5056.725% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1773.053% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -8989.626% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -842.065% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -4750.301% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -893.057% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 11.849% |
| AlloVir, Inc. | 180.93 Million USD | -776.996% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -255.989% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -5245.92% |
| Bicycle Therapeutics plc | 216.92 Million USD | -631.496% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -823.07% |
| ChromaDex Corporation | 56.37 Million USD | -2714.481% |
| Chimerix, Inc. | 93.38 Million USD | -1599.104% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -11307.742% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -954.084% |
| CRISPR Therapeutics AG | 463.49 Million USD | -242.351% |
| Precision BioSciences, Inc. | 92.46 Million USD | -1616.12% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -524.607% |
| Fortress Biotech, Inc. | 200.19 Million USD | -692.615% |
| Fortress Biotech, Inc. | 200.19 Million USD | -692.615% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -4745.709% |
| ImmuCell Corporation | 9.61 Million USD | -16399.077% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -905.472% |
| Immix Biopharma, Inc. | 16.14 Million USD | -9730.648% |
| Incyte Corporation | 1.19 Billion USD | -33.287% |
| Innoviva, Inc. | 132.15 Million USD | -1100.702% |
| IO Biotech, Inc. | 91.44 Million USD | -1635.262% |
| Jaguar Health, Inc. | 42.01 Million USD | -3676.689% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -837.384% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1781.783% |
| ContextLogic Inc. | 387 Million USD | -310.02% |
| MiMedx Group, Inc. | 229.72 Million USD | -590.722% |
| MEI Pharma, Inc. | 34.78 Million USD | -4461.667% |
| NextCure, Inc. | 67.63 Million USD | -2246.018% |
| Onconetix, Inc. | 34.9 Million USD | -4445.668% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -12349.208% |
| Opthea Limited | 191.96 Million USD | -726.586% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -57567.708% |
| Vaxcyte, Inc. | 468.04 Million USD | -239.025% |
| PDS Biotechnology Corporation | 43.04 Million USD | -3586.299% |
| Precigen, Inc. | 84.18 Million USD | -1784.957% |
| Pharming Group N.V. | 225.49 Million USD | -603.698% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -845.483% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -2086.666% |
| PureTech Health plc | 144.59 Million USD | -997.378% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -1118.133% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -547.246% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -6428.167% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -593.885% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -5042.02% |
| Acelyrin, Inc. | 422.06 Million USD | -275.956% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -12306213.014% |
| Summit Therapeutics Inc. | 87.68 Million USD | -1709.612% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -4181.179% |
| Senti Biosciences, Inc. | 94.7 Million USD | -1575.493% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -1184.288% |
| Elevation Oncology, Inc. | 45.44 Million USD | -3391.64% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -5284.56% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -40152.579% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -1100.511% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -4555.35% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -18676.192% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -775.216% |
| Seer, Inc. | 110.49 Million USD | -1336.126% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -2147.749% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -1597.486% |
| ESSA Pharma Inc. | 32.13 Million USD | -4837.981% |
| GlycoMimetics, Inc. | 39.28 Million USD | -3939.109% |
| GT Biopharma, Inc. | 13.57 Million USD | -11588.097% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -621.82% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -688.989% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -511.651% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -2695.638% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -2834.127% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -15867.324% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -293.192% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -8282.778% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -3030.168% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -511.1% |
| Aptose Biosciences Inc. | 52.35 Million USD | -2930.743% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -10911.345% |
| Soligenix, Inc. | 7.79 Million USD | -20255.676% |
| Century Therapeutics, Inc. | 56.07 Million USD | -2729.941% |
| Kura Oncology, Inc. | 165.8 Million USD | -857.019% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -1285.746% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -18974.119% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -63840.646% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -1373.357% |
| Autolus Therapeutics plc | 196.72 Million USD | -706.592% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1774.359% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -1262.589% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -8086.431% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -393.158% |
| GRI Bio, Inc. | 11.33 Million USD | -13905.084% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -22389.275% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -1109.497% |
| IGM Biosciences, Inc. | 265.59 Million USD | -497.451% |
| INmune Bio, Inc. | 29.89 Million USD | -5207.653% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -819.582% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -3836.012% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -9830.159% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -9980.174% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -2455.277% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -1375.769% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -475.559% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -426.379% |
| Verastem, Inc. | 92.08 Million USD | -1623.183% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -8745.398% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -754.369% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -1206.989% |
| Histogen Inc. | 14.27 Million USD | -11018.105% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -9787.599% |
| Surrozen, Inc. | 18.55 Million USD | -8454.049% |
| Organovo Holdings, Inc. | 14.91 Million USD | -10538.793% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -31072.936% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -2559.112% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -6086.985% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -3275.688% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -20688.794% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -790.767% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -3175.218% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -547.653% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -10226.153% |
| Apollomics, Inc. | 54.14 Million USD | -2830.876% |
| Amarin Corporation plc | 272.35 Million USD | -482.609% |
| Mesoblast Limited | 5.9 Million USD | -26785.395% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1925.551% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -549.993% |
| Synaptogenix, Inc. | 8.31 Million USD | -18985.926% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -10778.76% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -527.045% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -4660.793% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -17867.77% |
| Better Therapeutics, Inc. | 38.26 Million USD | -4047.133% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -583.808% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -85.544% |
| NLS Pharmaceutics AG | 11.8 Million USD | -13339.21% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -19631.342% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -5190.488% |
| Gritstone bio, Inc. | 148.37 Million USD | -969.443% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -2204.317% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -9598.991% |
| Avid Bioservices, Inc. | 25.99 Million USD | -6003.924% |
| Insmed Incorporated | 949.26 Million USD | -67.159% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -10013.432% |
| MediWound Ltd. | 18.86 Million USD | -8309.879% |
| OmniAb, Inc. | 83.89 Million USD | -1791.383% |
| Alector, Inc. | 248.8 Million USD | -537.767% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -577.218% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -2936.834% |
| Zai Lab Limited | 547.47 Million USD | -189.835% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -298.033% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1766.993% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -542.061% |
| Immunic, Inc. | 99.22 Million USD | -1499.202% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -897.897% |
| Veracyte, Inc. | 357.93 Million USD | -343.316% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 82.4% |
| FibroGen, Inc. | 398.11 Million USD | -298.574% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -11066.615% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -22936.995% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -22168.253% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 51.26% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -6032.942% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -401.283% |
| TG Therapeutics, Inc. | 198.47 Million USD | -699.484% |
| Galecto, Inc. | 35.62 Million USD | -4353.858% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -3799.767% |
| Fortrea Holdings Inc. | 457.3 Million USD | -246.988% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -2823.424% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -5394.757% |
| XBiotech Inc. | 37.51 Million USD | -4130.275% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -2204.317% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -7584.517% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -1016.968% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -1501.591% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -1333.195% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -65.591% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -5401.044% |
| Vaxxinity, Inc. | 56.05 Million USD | -2730.95% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -268.469% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -7012.936% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -1331.243% |
| NexImmune, Inc. | 28.16 Million USD | -5533.356% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -28589.042% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -8768.381% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 43.637% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -6132.672% |
| Scopus BioPharma Inc. | 11.71 Million USD | -13444.965% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -1148.82% |
| Ainos, Inc. | 12.95 Million USD | -12150.577% |
| Pluri Inc. | 22.48 Million USD | -6958.612% |
| Prothena Corporation plc | 282.4 Million USD | -461.878% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -693.301% |
| Celularity Inc. | 215.05 Million USD | -637.836% |
| Rallybio Corporation | 78.93 Million USD | -1910.308% |
| Cue Biopharma, Inc. | 19.54 Million USD | -8019.824% |
| MeiraGTx Holdings plc | 151.07 Million USD | -950.302% |
| Omeros Corporation | 94.75 Million USD | -1574.68% |
| Humacyte, Inc. | 23.49 Million USD | -6653.1% |
| Immunocore Holdings plc | 308.04 Million USD | -415.12% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -46707.552% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -1726.715% |
| Blueprint Medicines Corporation | 722.86 Million USD | -119.513% |
| CalciMedica, Inc. | 21.81 Million USD | -7173.117% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -2025.336% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -888.399% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -826.341% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -438.0% |
| Pulmatrix, Inc. | 22.03 Million USD | -7100.182% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -4489.374% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -1685.583% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -187.686% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -2087.118% |
| Cytokinetics, Incorporated | 173.61 Million USD | -813.978% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -4510.175% |
| Nutriband Inc. | 5.73 Million USD | -27572.958% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -3538.31% |
| Vor Biopharma Inc. | 126.03 Million USD | -1158.986% |
| Roivant Sciences Ltd. | 1.18 Billion USD | -33.435% |
| Evogene Ltd. | 27.79 Million USD | -5609.881% |
| ProKidney Corp. | 151.52 Million USD | -947.225% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -2039.233% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -20528.264% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -158.337% |
| CorMedix Inc. | 48.95 Million USD | -3141.11% |
| BioLineRx Ltd. | 50.8 Million USD | -3023.452% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -952.937% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -4067.829% |
| Atai Life Sciences N.V. | 125.78 Million USD | -1161.499% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -1843.642% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -1849.141% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -528.297% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -4746.597% |
| MediciNova, Inc. | 10.9 Million USD | -14457.224% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -1131.778% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -21757.852% |
| GeoVax Labs, Inc. | 6.02 Million USD | -26248.894% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -233.104% |
| Biomea Fusion, Inc. | 126.13 Million USD | -1157.998% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | -20.958% |
| Mereo BioPharma Group plc | 35.84 Million USD | -4327.141% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -730.386% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -590.041% |
| Absci Corporation | 73.66 Million USD | -2054.014% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -5652.94% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -1087.795% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -555.254% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -505.529% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -662.895% |
| Allakos Inc. | 196.05 Million USD | -709.348% |
| Imunon, Inc. | 20.31 Million USD | -7712.618% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -1298.422% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -330.473% |
| BioAtla, Inc. | 129.68 Million USD | -1123.543% |
| NLS Pharmaceutics AG | 11.8 Million USD | -13339.21% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -9915.628% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1768.598% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -3699.933% |
| XOMA Corporation | 46.46 Million USD | -3315.139% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -1327.329% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1013.816% |
| aTyr Pharma, Inc. | 12.97 Million USD | -12125.718% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -1430.81% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -817.901% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -522.842% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -4141.809% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -19192.546% |
| Akari Therapeutics, Plc | 16.8 Million USD | -9341.723% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -69679.988% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -430.13% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -23482.102% |
| UroGen Pharma Ltd. | 138.88 Million USD | -1042.486% |
| Sutro Biopharma, Inc. | 243 Million USD | -552.97% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -21712.487% |
| Orgenesis Inc. | 45.75 Million USD | -3367.832% |
| Entera Bio Ltd. | 8.86 Million USD | -17809.436% |
| GH Research PLC | 41.22 Million USD | -3749.343% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -6072.304% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1810.558% |
| Xencor, Inc. | 306.97 Million USD | -416.904% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -32062.601% |
| Replimune Group, Inc. | 234.77 Million USD | -575.877% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -7644.191% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -727.325% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -23482.102% |
| Portage Biotech Inc. | 18.19 Million USD | -8619.029% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -21757.852% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -1411.777% |
| OncoCyte Corporation | 25.63 Million USD | -6089.398% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -25931.468% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -13749.765% |
| Purple Biotech Ltd. | -22.46 Million USD | 7162.696% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -9528.495% |
| scPharmaceuticals Inc. | 65.17 Million USD | -2334.527% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -18672.336% |
| HilleVax, Inc. | 133.34 Million USD | -1089.978% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -15328.06% |
| Tharimmune, Inc. | 9.45 Million USD | -16682.01% |
| Genprex, Inc. | 31.06 Million USD | -5008.651% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -746.163% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -4957.131% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -207321.699% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -29031.625% |
| OKYO Pharma Limited | 8243.57 USD | -19248550.767% |
| Savara Inc. | 15.74 Million USD | -9977.968% |
| Curis, Inc. | 58.35 Million USD | -2619.177% |
| Daré Bioscience, Inc. | 33.6 Million USD | -4621.227% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -31059.15% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -21167.605% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -5772.163% |
| BeiGene, Ltd. | 3.28 Billion USD | 51.72% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -7858.033% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -218.141% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -932.708% |
| Erasca, Inc. | 141.52 Million USD | -1021.198% |
| bluebird bio, Inc. | 240.23 Million USD | -560.518% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -34951.582% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 9.134% |
| DBV Technologies S.A. | 92.16 Million USD | -1621.762% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -34951.582% |
| Moderna, Inc. | 6.39 Billion USD | 75.183% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -3624.04% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -10945.357% |
| Molecular Templates, Inc. | 63.09 Million USD | -2415.059% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -2278.939% |
| Travere Therapeutics, Inc. | 472 Million USD | -236.18% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -1007.226% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -2455.936% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -3554.987% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -662.397% |
| MacroGenics, Inc. | 217.21 Million USD | -630.509% |
| RenovoRx, Inc. | 11.39 Million USD | -13823.973% |
| Adicet Bio, Inc. | 152.03 Million USD | -943.671% |
| Prime Medicine, Inc. | 186.63 Million USD | -750.185% |
| Aditxt, Inc. | 25.95 Million USD | -6014.563% |
| Adagene Inc. | 41.83 Million USD | -3693.269% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -21606.631% |
| Quantum-Si incorporated | 111.65 Million USD | -1321.091% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -823.349% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -10784.904% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -4329.613% |
| SciSparc Ltd. | 9.01 Million USD | -17509.322% |
| Vericel Corporation | 142.04 Million USD | -1017.133% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -18230.11% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -6772.554% |
| Generation Bio Co. | 144.46 Million USD | -998.366% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1811.088% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -1735.272% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -436.581% |
| Invivyd, Inc. | 205.75 Million USD | -671.197% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -2098.999% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -16819.287% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -2008.56% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -15325.061% |
| 2seventy bio, Inc. | 289.88 Million USD | -447.377% |
| ADMA Biologics, Inc. | 66.58 Million USD | -2283.047% |
| Clene Inc. | 41.07 Million USD | -3763.307% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -12289.055% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -2795.788% |
| GeoVax Labs, Inc. | 6.02 Million USD | -26248.894% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -350.727% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -4219.872% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -4604.625% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -1430.131% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -4769.054% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -831.874% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -106.687% |
| Evaxion Biotech A/S | 22.27 Million USD | -7025.173% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -1070.672% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -575.563% |
| Trevena, Inc. | 38.41 Million USD | -4030.831% |
| Surrozen, Inc. | 18.55 Million USD | -8454.049% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1884.835% |
| Cingulate Inc. | 22.75 Million USD | -6872.023% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 21279.605% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3452.457% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -19171.161% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -1447.199% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -110.424% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -2456.265% |
| Clearmind Medicine Inc. | 8.74 Million USD | -18052.528% |
| Kronos Bio, Inc. | 128.11 Million USD | -1138.527% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1787.401% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -54001.061% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1473.761% |
| Statera Biopharma, Inc. | 28.82 Million USD | -5404.0% |
| ImmunityBio, Inc. | 362.87 Million USD | -337.283% |
| Korro Bio, Inc. | 84.53 Million USD | -1777.086% |
| Kineta, Inc. | 21.15 Million USD | -7400.359% |
| BioVie Inc. | 31.95 Million USD | -4866.403% |
| Codexis, Inc. | 66.51 Million USD | -2285.484% |
| Celularity Inc. | 215.05 Million USD | -637.836% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -600.189% |
| Celcuity Inc. | 66.23 Million USD | -2295.845% |
| Virax Biolabs Group Limited | 6.54 Million USD | -24136.455% |
| Cibus, Inc. | 320.3 Million USD | -395.395% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -3590.177% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -4588.5% |
| IN8bio, Inc. | 30.33 Million USD | -5130.497% |
| Kodiak Sciences Inc. | 277.32 Million USD | -472.18% |
| Annexon, Inc. | 143.72 Million USD | -1004.052% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -1143.643% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -6826.431% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -247833.75% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -103.541% |
| Eyenovia, Inc. | 25.4 Million USD | -6145.565% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -1030.867% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -28428.875% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1905.201% |
| Arcellx, Inc. | 200.19 Million USD | -692.599% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -3357.028% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -633.223% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -15836.286% |
| Moolec Science SA | 52.75 Million USD | -2908.072% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -2495.401% |
| Geron Corporation | 70.44 Million USD | -2152.631% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -3309.489% |
| Royalty Pharma plc | 862.4 Million USD | -83.995% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -1586.768% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -16911.136% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -6912.28% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -663.563% |
| Humacyte, Inc. | 23.49 Million USD | -6653.1% |
| Structure Therapeutics Inc. | 102.77 Million USD | -1443.932% |
| 89bio, Inc. | 151.2 Million USD | -949.427% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1880.203% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -10813.177% |
| Genelux Corporation | 24.33 Million USD | -6420.551% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -4577.582% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -817.907% |
| Notable Labs, Ltd. | 14.77 Million USD | -10643.236% |
| Liquidia Corporation | 87.98 Million USD | -1703.482% |
| Mustang Bio, Inc. | 48.5 Million USD | -3171.636% |
| Immunovant, Inc. | 282.7 Million USD | -461.275% |
| Quantum-Si incorporated | 111.65 Million USD | -1321.091% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -6938.573% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -7361.212% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -1455.48% |
| Acasti Pharma Inc. | 11.3 Million USD | -13941.023% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -6822.773% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -9830.159% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -3309.342% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -139755.806% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -9888.518% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -5342.179% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -3734.274% |
| PepGen Inc. | 84.76 Million USD | -1771.949% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -5255.121% |
| United Therapeutics Corporation | 885.1 Million USD | -79.276% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -6830.061% |
| Solid Biosciences Inc. | 104.31 Million USD | -1421.139% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -4748.74% |
| Immuneering Corporation | 58.41 Million USD | -2616.483% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -31072.936% |
| Silo Pharma, Inc. | 3.92 Million USD | -40359.823% |
| Belite Bio, Inc | 31.66 Million USD | -4910.661% |
| XOMA Corporation | 46.46 Million USD | -3315.139% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -2249.039% |
| Bionomics Limited | 17.89 Billion USD | 91.132% |
| Apogee Therapeutics, Inc. | 93 Million USD | -1606.156% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 4547.242% |
| uniQure N.V. | 285.08 Million USD | -456.596% |
| Cassava Sciences, Inc. | 105.95 Million USD | -1397.566% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -21606.631% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -717.054% |
| Forte Biosciences, Inc. | 32.47 Million USD | -4785.846% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -18997.639% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -5298.115% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -28428.875% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -11066.615% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -17751.007% |
| Altimmune, Inc. | 30.55 Million USD | -5093.01% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -271.045% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 4547.242% |
| Compugen Ltd. | 43.97 Million USD | -3508.688% |
| Peak Bio, Inc. | 1249.13 USD | -127030393.223% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -2040.82% |
| Benitec Biopharma Inc. | 22.38 Million USD | -6989.518% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -552.487% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -5459.247% |
| Zura Bio Limited | 62.63 Million USD | -2433.248% |
| PolyPid Ltd. | 21.04 Million USD | -7439.919% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -9649.177% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -5459.247% |
| Instil Bio, Inc. | 85.78 Million USD | -1749.713% |
| argenx SE | 1.53 Billion USD | -3.472% |
| Immunome, Inc. | 122.82 Million USD | -1191.952% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -3173.525% |
| Verona Pharma plc | 67.15 Million USD | -2262.987% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -6030.099% |
| Shattuck Labs, Inc. | 93.61 Million USD | -1595.02% |
| CervoMed Inc. | 14.95 Million USD | -10508.375% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -2144.284% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -18471.816% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -3011.325% |
| Moolec Science SA | 52.75 Million USD | -2908.072% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -9546.97% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -1097.069% |
| AnaptysBio, Inc. | 181.56 Million USD | -773.929% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1929.385% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -1723.021% |
| NeurAxis, Inc. | 8.82 Million USD | -17888.212% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -12508.47% |
| Lumos Pharma, Inc. | 38.66 Million USD | -4003.908% |
| Achilles Therapeutics plc | 75.25 Million USD | -2008.532% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -6030.099% |
| 180 Life Sciences Corp. | 13.47 Million USD | -11673.519% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -5887.282% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -54001.061% |
| Nutriband Inc. | 5.73 Million USD | -27572.958% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -1332.367% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -2751.196% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -3018.725% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -2300.605% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -2831.791% |
| Palisade Bio, Inc. | 13.32 Million USD | -11812.733% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -3394.409% |
| Beam Therapeutics Inc. | 554.19 Million USD | -186.321% |
| Neurogene Inc. | 55.58 Million USD | -2754.787% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -538.57% |
| AEON Biopharma, Inc. | 48.42 Million USD | -3176.5% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -1540.757% |
| Sesen Bio, Inc. | 78.38 Million USD | -1924.44% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1799.671% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -12506.571% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -251.84% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -1705.411% |
| Athira Pharma, Inc. | 125.46 Million USD | -1164.706% |
| Vaccinex, Inc. | 23.45 Million USD | -6665.193% |
| HCW Biologics Inc. | 21.02 Million USD | -7446.187% |
| XOMA Corporation | 46.46 Million USD | -3315.139% |
| Nektar Therapeutics | 190.9 Million USD | -731.195% |
| Arvinas, Inc. | 480 Million USD | -230.578% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -69679.988% |
| Merus N.V. | 200.49 Million USD | -691.433% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -1435.268% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -4483.408% |
| Rezolute, Inc. | 70.38 Million USD | -2154.359% |
| Clene Inc. | 41.07 Million USD | -3763.307% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -9588.18% |
| BeyondSpring Inc. | 24.86 Million USD | -6281.564% |
| Synlogic, Inc. | 58.53 Million USD | -2610.955% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -8768.634% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -35224.488% |
| Peak Bio, Inc. | 1249.13 USD | -127030393.223% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -2525.113% |
| Krystal Biotech, Inc. | 160.42 Million USD | -889.102% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -486.325% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -355.92% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -73473.097% |
| MannKind Corporation | 125.59 Million USD | -1163.387% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1776.132% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -16348.388% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -1670.936% |
| Gossamer Bio, Inc. | 183.75 Million USD | -763.509% |
| CohBar, Inc. | 12.38 Million USD | -12708.669% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -3028.255% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -5652.94% |
| Legend Biotech Corporation | 583.14 Million USD | -172.107% |
| Mural Oncology plc | 192.07 Million USD | -726.14% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -2263.138% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -9728.116% |
| Disc Medicine, Inc. | 91.12 Million USD | -1641.318% |
| Champions Oncology, Inc. | 28.11 Million USD | -5544.881% |
| REGENXBIO Inc. | 321.15 Million USD | -394.081% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -29497.216% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2745.929% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -3972.766% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -1287.564% |
| Vaxart, Inc. | 90.72 Million USD | -1648.976% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -18524.114% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -3607.933% |
| Cellectis S.A. | 97.32 Million USD | -1530.473% |
| Longeveron Inc. | 21.25 Million USD | -7367.181% |
| Repare Therapeutics Inc. | 167.35 Million USD | -848.138% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -16.605% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1997.661% |
| Revolution Medicines, Inc. | 498.76 Million USD | -218.141% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -23754.119% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -3510.083% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -2027.331% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -2178.705% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -14246.98% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 66.769% |
| Denali Therapeutics Inc. | 527.23 Million USD | -200.965% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -18230.11% |
| Veru Inc. | 101.34 Million USD | -1465.669% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -6679.066% |
| Cingulate Inc. | 22.75 Million USD | -6872.023% |
| Passage Bio, Inc. | 108.38 Million USD | -1363.964% |
| Context Therapeutics Inc. | 25.07 Million USD | -6228.721% |
| Exicure, Inc. | 14.07 Million USD | -11172.918% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -670.04% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -3564.525% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -17190.246% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -528.468% |
| Nuvalent, Inc. | 149.49 Million USD | -961.445% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -19570.203% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -1430.898% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -7297.902% |
| OmniAb, Inc. | 83.89 Million USD | -1791.383% |
| Anew Medical, Inc. | 1.3 Million USD | -121880.78% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -4743.047% |
| Lipocine Inc. | 15.08 Million USD | -10422.29% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -2216.022% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1983.696% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -3836.012% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -1281.692% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -6988.885% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -138.92% |
| Ocugen, Inc. | 71.56 Million USD | -2117.189% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -1590.469% |
| Q32 Bio Inc. | 92.68 Million USD | -1612.102% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -7393.983% |
| Alumis Inc. Common Stock | 158.17 Million USD | -903.184% |
| Equillium, Inc. | 50.6 Million USD | -3035.549% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -2442.666% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -11311.094% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -8311.168% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -3279.643% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -1362.925% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -12704.091% |
| Dominari Holdings Inc. | 23.83 Million USD | -6557.336% |
| Edesa Biotech, Inc. | 9.22 Million USD | -17105.005% |
| vTv Therapeutics Inc. | 11.9 Million USD | -13226.413% |
| Bio-Techne Corporation | 563.03 Million USD | -181.823% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -288.149% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -490.415% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -1099.586% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -10910.867% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -869.343% |
| Nkarta, Inc. | 131.65 Million USD | -1105.299% |
| BioCardia, Inc. | 12.12 Million USD | -12991.131% |
| Iterum Therapeutics plc | 47.46 Million USD | -3242.833% |